COMPEL Trial: Osimertinib-Chemotherapy Combination Doubles Survival in Advanced NSCLC

Revolutionizing NSCLC: Is the COMPEL Trial a Game-Changer?

AstraZeneca's COMPEL trial has demonstrated significant clinical benefits for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who experienced non-CNS progression on first-line osimertinib treatment. The phase III study showed that continuing osimertinib with the addition of chemotherapy doubled progression-free survival (PFS) compared to chemotherapy alone, while also suggesting improved overall survival and reduced incidence of new brain metastases.

What is the Rationale Behind Combining Osimertinib with Chemotherapy?

The trial investigated whether maintaining osimertinib therapy while adding platinum-pemetrexed chemotherapy could provide clinical benefit for patients who had initially responded to osimertinib but later experienced non-CNS disease progression. This approach addresses a critical unmet need, as treatment options have remained limited following progression on first-line osimertinib, with platinum-based chemotherapy typically being the standard second-line treatment. The study enrolled 98 patients with EGFR-mutated advanced NSCLC who were randomized to receive either osimertinib 80 mg once daily plus platinum-pemetrexed chemotherapy or placebo plus the same chemotherapy regimen. Patients had previously shown radiological non-CNS progression following at least 6 months of disease control on first-line osimertinib treatment. The primary endpoint was investigator-assessed PFS, with secondary endpoints including CNS PFS, non-CNS PFS, and overall survival. Despite the sample size being reduced from the initially planned 204 patients to 98 due to evolving treatment landscape changes, the results provide compelling evidence for the combination approach. Median PFS was 8.4 months with osimertinib plus chemotherapy versus 4.4 months with placebo plus chemotherapy (HR 0.43, 95% CI 0.27-0.70), representing a 57% reduction in the risk of disease progression or death. The 6-month PFS rates were 64% and 32% for each treatment arm, respectively. This substantial improvement suggests that even after initial progression, many tumor cells retain sensitivity to EGFR inhibition with osimertinib.

How Does This Approach Affect CNS Metastases and Overall Survival?

The study's results also highlighted osimertinib's continued protective effect against CNS metastases, even after non-CNS progression on first-line therapy. Among patients without CNS metastases at baseline, median CNS PFS was 15.9 months with osimertinib plus chemotherapy compared to 8.6 months with placebo plus chemotherapy (HR 0.56, 95% CI 0.27-1.13). Importantly, fewer patients developed new brain lesions at the time of progression in the osimertinib plus chemotherapy arm (10%) compared to the placebo plus chemotherapy arm (27%). These findings reinforce osimertinib's established blood-brain barrier penetration capabilities and suggest that the combination may enhance protection against CNS metastases, consistent with results from the first-line FLAURA2 study. The combination therapy also demonstrated benefits in non-CNS PFS (HR 0.43, 95% CI 0.26-0.71) and showed promising overall survival data, with median OS of 15.9 months versus 9.8 months (HR 0.71, 95% CI 0.42-1.23), although the study was not powered for definitive OS conclusions. The non-CNS objective response rate was 35% with osimertinib plus chemotherapy and 29% with placebo plus chemotherapy, with longer duration of response in the combination arm (8.2 months versus 4.2 months).

Are Safety Concerns Addressed in the Osimertinib-Chemotherapy Regimen?

The safety profile of osimertinib plus chemotherapy was manageable and consistent with previously reported data for the individual components. Adverse events of any grade were reported in 98% of patients in both treatment arms. The most common adverse events with osimertinib plus chemotherapy versus placebo plus chemotherapy were anemia (65% versus 54%), asthenia (40% versus 48%), nausea (35% versus 48%), and diarrhea (31% versus 10%). Grade ≥3 adverse events occurred in 63% of patients receiving osimertinib plus chemotherapy and 46% receiving placebo plus chemotherapy, with neutropenia (15%) and anemia (13%) being most common in the combination arm. Serious adverse events were reported in 38% of patients with osimertinib plus chemotherapy and 31% with placebo plus chemotherapy. Treatment-related discontinuations were more common in the osimertinib combination arm, with 13% discontinuing the EGFR inhibitor due to adverse events compared to just 2% in the placebo arm. One death occurred in each treatment arm, neither considered related to study treatment.

How Does This Strategy Stack Up in a Competitive Market?

The COMPEL findings position osimertinib-chemotherapy combination as a potential new standard for patients progressing after first-line osimertinib treatment, but it enters an increasingly competitive landscape. The phase III MARIPOSA-2 study recently demonstrated that amivantamab (an EGFR-MET bispecific antibody) plus chemotherapy significantly improved PFS versus chemotherapy alone in a similar patient population (6.3 months versus 4.2 months; HR 0.48). Meanwhile, other targeted approaches are being evaluated, including osimertinib plus savolitinib for patients with MET amplification following progression on first-line EGFR-TKI therapy, which showed promising activity in the SAVANNAH study and superior PFS versus chemotherapy in the SACHI study. Additionally, antibody-drug conjugates like datopotamab deruxtecan (Dato-Dxd) have shown activity in this setting, with the ongoing TROPION-Lung15 study evaluating Dato-Dxd alone and in combination with osimertinib versus chemotherapy.

What Do These Industry Trends Mean for Future NSCLC Treatments?

Industry Context: The COMPEL results reinforce the growing trend toward combination approaches and continued EGFR inhibition beyond progression in NSCLC. This strategy aligns with the broader oncology paradigm shift toward viewing advanced cancer as a chronic disease requiring sequential and combination therapies rather than discrete treatment lines. The findings support osimertinib's position as a backbone therapy in EGFR-mutated NSCLC and highlight the importance of understanding heterogeneous resistance mechanisms. As competition intensifies in the second-line EGFR-mutated NSCLC space, pharmaceutical companies are increasingly focusing on biomarker-driven treatment selection and rational combinations to address specific resistance patterns, potentially leading to more personalized treatment algorithms for patients progressing on first-line targeted therapies.

Summary

The phase III COMPEL trial by AstraZeneca has shown that continuing osimertinib treatment while adding platinum-pemetrexed chemotherapy significantly improves outcomes for patients with EGFR-mutated advanced non-small cell lung cancer who experience non-CNS progression on first-line osimertinib. The study enrolled 98 patients and demonstrated that the combination therapy doubled median progression-free survival to 8.4 months compared to 4.4 months with chemotherapy alone, representing a 57% reduction in the risk of disease progression or death. The combination also provided continued protection against CNS metastases, with fewer patients developing new brain lesions in the osimertinib plus chemotherapy arm compared to chemotherapy alone. Overall survival data showed promising trends, with median OS of 15.9 months versus 9.8 months, though the study was not definitively powered for this endpoint. The safety profile was manageable and consistent with known effects of the individual components, with grade 3 or higher adverse events occurring in 63% of patients receiving the combination versus 46% receiving chemotherapy alone. These findings position the osimertinib-chemotherapy combination as a potential new standard for this patient population, though it enters a competitive landscape that includes other targeted therapies such as amivantamab plus chemotherapy and investigational approaches like antibody-drug conjugates. The results support the evolving treatment paradigm of viewing advanced cancer as a chronic disease requiring sequential and combination therapies, with continued EGFR inhibition beyond initial progression potentially offering sustained clinical benefits for appropriately selected patients.